Aoyagi Haruhiko, Kaneko Jun, Makinose Takamichi, Someno Yasunori, Katsuta Eriko, Saguchi Morihito, Okubo Katsuhiko, Hamada Setsuo, Sekine Takeshi, Sato Takanobu, Sugihara Kenichi, Maejima Shizuaki
Department of Surgery, Hasuda Hospital.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2474-6.
In November 2005, a 34-year-old female presented to our department with a bleeding tumor on her right breast. She noticed the tumor approximately two years ago but she left it untreated. An exposed tumor was observed with a diameter of approximately 8 cm located in the right breast. It was diagnosed as invasive ductal carcinoma by biopsy (ER (+), PgR (+), and HERS2: 1 +). The imaging showed multiple metastases to the bilateral lungs, right axillary lymph node, mediastinal lymph node and sternal. The diagnosis was made as right breast cancer (T4c, N3c, M1, and stage IV). The patient received 4 courses of FEC therapy and 4 courses of PTX therapy. The patient had a partial response (PR). However, tumor markers were elevated in September 2006. Thus, an administration of S-1 was initiated. The size of the tumor shown in the imaging was reduced, and the patient had a PR. Since December 2008, tumor markers have been elevated again. However, the patient has had SD in the imaging and S-1 administrations have been continued. A total of 24 courses have been performed to the present time, and the patient's conditions have not been aggravated in approximately 3 years and 5 months. She has maintained a good QOL and is being followed up on an outpatient basis. S-1 administrations can be an effective treatment for advanced breast cancer resistant to anthracycline and taxane when considering a satisfactory QOL of patients.
2005年11月，一名34岁女性因右乳出现出血性肿瘤前来我科就诊。她大约两年前发现了这个肿瘤，但未予治疗。观察到右乳有一个直径约8 cm的外露肿瘤。活检诊断为浸润性导管癌（雌激素受体阳性、孕激素受体阳性、人表皮生长因子受体2：1+）。影像学检查显示双侧肺、右腋窝淋巴结、纵隔淋巴结和胸骨有多处转移。诊断为右乳腺癌（T4c、N3c、M1，IV期）。患者接受了4个疗程的FEC方案化疗和4个疗程的紫杉醇化疗。患者有部分缓解（PR）。然而，2006年9月肿瘤标志物升高。因此，开始给予S-1治疗。影像学检查显示肿瘤大小缩小，患者获得PR。自2008年12月以来，肿瘤标志物再次升高。然而，患者影像学检查为疾病稳定（SD），继续给予S-1治疗。截至目前共进行了24个疗程，患者病情在约3年5个月内未加重。她维持了良好的生活质量，正在门诊随访。考虑到患者令人满意的生活质量，S-1治疗对于对蒽环类和紫杉类耐药的晚期乳腺癌可能是一种有效的治疗方法。
